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SOCIETY OF TOXICOLOGY POSITION PAPER
The Safety of Genetically Modified Foods Produced
through Biotechnology
Executive Summary
The Society of Toxicology (SOT) is committed to protecting
and enhancing human, animal, and environmental health
through the sound application of the fundamental principles of
the science of toxicology. It is with this goal in mind that the
SOT defines here its current consensus position on the safety of
foods produced through biotechnology (genetic engineering).
These products are commonly termed genetically modified
foods, but this is misleading, since conventional methods of
microbial, crop, and animal improvement also produce genetic
modifications and these are not addressed here.
The available scientific evidence indicates that the potential
adverse health effects arising from biotechnology-derived
foods are not different in nature from those created by con-
ventional breeding practices for plant, animal, or microbial
enhancement, and are already familiar to toxicologists. It is
therefore important to recognize that the food product itself,
rather than the process through which it is made, should be the
focus of attention in assessing safety.
We support the use of the substantial equivalence concept as
part of the safety assessment of biotechnology-derived foods.
This process establishes whether the new plant or animal is
significantly different from comparable, nonengineered plants
or animals used to produce food that is generally considered to
be safe for consumers. It provides critical guidance as to the
nature of any increased health hazards in the new food. To
establish substantial equivalence, extensive comparative stud-
ies of the chemical composition, nutritional quality, and levels
of potentially toxic components, in both the engineered and
conventional crop and animal, are conducted. Notable differ-
ences between the existing and new organism would require
further evaluation to determine whether the engineered form
presents a higher level of risk. Through this approach, the
safety of current biotechnology-derived foods can be compared
with that of their conventional counterparts, using established
and accepted methods of analytical, nutritional, and toxicolog-
ical research.
Studies of this type have established that the level of safety
to consumers of current genetically engineered foods is likely
to be equivalent to that of traditional foods. At present, no
verifiable evidence of adverse health effects of BD foods has
been reported, although the current passive reporting system
probably would not detect minor or rare adverse effects or a
moderate increase in effects with a high background incidence
such as diarrhea.
The changes in the composition of existing foods produced
through biotechnology are quite limited. Assessing safety may
be more difficult in the future if genetic engineering projects
cause more substantial and complex changes in a foodstuff.
Methods have not yet been developed with which whole foods
(in contrast to single chemical components) can be fully eval-
uated for safety. Progress also needs to be made in developing
definitive methods for the identification and characterization of
proteins that are potential allergens, and this is currently a
major focus of research. Improved methods of profiling plant
and microbial metabolites, proteins and gene expression may
be helpful in detecting unexpected changes in BD organisms
and in establishing substantial equivalence.
A continuing evolution of toxicological methodologies and
regulatory strategies will be necessary to ensure that the
present level of safety of biotechnology-derived foods is main-
tained in the future.
Introduction
The Society of Toxicology (SOT) is committed to protecting
and enhancing human, animal, and environmental health
through the sound application of the fundamental principles of
the science of toxicology. It is with this goal in mind that the
SOT defines here its current consensus position on the safety of
foods produced through biotechnology. In this context, bio-
technology is taken to mean those processes whereby genes
that are not endogenous to the organism (transgenes) are trans-
ferred to microorganisms, plants, or animals employed in food
production, or where the expression of existing genes is per-
manently modified, using the techniques of genetic engineer-
ing. We intentionally avoid using the term genetically modified
organisms (GMOs) or foods in this context, since conventional
techniques of plant and animal breeding, which are not con-
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sidered here, also involve genetic modification. The extent of
the genetic changes resulting from such conventional breeding
techniques, which is generally undefined, far exceeds that
typically produced by transgenic methods. Consequently, it is
important to recognize that it is the product, and not the process
of modification, that is the focus of concern regarding the
human or environmental safety of biotechnology-derived (BD)
foods.
The principal responsibilities of toxicologists are to define
and characterize the potential for natural and manufactured
materials to cause adverse health effects and to assess, as
accurately as possible, the plausibility and level of risk for
human or animal health or for environmental damage under a
defined set of circumstances. It is not the task of the Society of
Toxicology to determine the overall value of a product or
process by balancing health or environmental risks with po-
tential benefits, or to choose between different strategies to
manage risk, although toxicological considerations are impor-
tant in both processes. Our purpose here is rather to identify
and consider the primary toxicological issues associated with
BD foods. Major areas of concern in the development and
application of such foods in agriculture relate to the possibility
of deleterious effects on both human health and the environ-
ment. We do not consider here some aspects of the possible
environmental impact of GM organisms such as gene transfer
to nonengineered plants.
Types of Toxicological Hazards to Consumers and
Producers Associated with BD Foods
Current techniques of developing organisms used in the
production of BD foods typically involve the transfer to the
host of the desired gene or genes in combination with a
promoter and a gene for a selectable marker trait that allows the
efficient isolation of cells or organisms that have been trans-
formed from those that have not. Common selectable markers
in plants have included resistance to antibiotics (kanamycin/
neomycin or ampicillin) or herbicides.
Several key issues have been raised with respect to the
potential toxicity associated with BD foods, including the
inherent toxicity of the transgenes and their products, and
unintended (pleiotropic or mutagenic) effects resulting from
the insertion of the new genetic material into the host genome.
Unintended effects of gene insertion might include an over-
expression by the host of inherently toxic or pharmacologically
active substances, silencing of normal host genes, or alterations
in host metabolic pathways. It is important to recognize that,
with the exception of the introduction of marker genes, the
process of genetic engineering does not, in itself, create new
types of risk. Most of the hazards listed above are also inherent
in conventional breeding methods.
The Concept of Substantial Equivalence
The guiding principle in the evaluation of BD foods by
regulatory agencies in Europe and the U.S. is that their human
and environmental safety is most effectively considered, rela-
tive to comparable products and processes currently in use.
From this arises the concept of “substantial equivalence.” If a
new food is found to be substantially equivalent in composition
and nutritional characteristics to an existing food, it can be
regarded as being as safe as the conventional food (FDA, 1992;
Kuiper et al., 2001; Maryanski, 1995; OECD, 1993) and does
not require extensive safety testing. Evaluation of substantial
equivalence includes consideration of the characteristics of the
transgene and its likely effects within the host, and measure-
ments of protein, fat, and starch content, amino acid composi-
tion, and vitamin and mineral equivalency together with levels
of known allergens and other potentially toxic components. BD
foods can either be substantially equivalent to an existing
counterpart, substantially equivalent except for certain defined
differences (on which further safety assessments would then
focus), or nonequivalent, which would mean that more exten-
sive safety testing might be necessary. The examination of
substantial equivalence, therefore, may be only the starting
point of the safety assessment. It provides a valuable guide to
the definition of potential hazards from BD foods and illumi-
nates necessary areas for further study (FAO/WHO, 2000).
While there is some concern relative to the meaning of “sub-
stantial” and how equivalency should be established, and de-
bate over its use continues (e.g., see Millstone et al., 1999 and
following correspondence; Kuiper et al., 2001; Royal Society
of Canada, 2001), the concept appears to be logical and robust
in assessing the safety of foods derived from both genetically
modified plants and microorganisms (FAO/WHO, 2000,
2001a). If it can be established with reasonable certainty that a
BD food is no less safe than its conventional counterpoint, it
provides a standard likely to be satisfactorily protective of
public health. It is also an approach that has the flexibility to
evolve in concert with the field of transgenic technology. A
recent study of FDA procedures for assessing the safety of BD
foods by the U.S. General Accounting Office reviews these
procedures and concludes that the current regimen of safety
tests are adequate to assess existing BD foods (U.S. General
Accounting Office, 2002).
Key Issues with Respect to Human Health Effects of BD
Foods
Is the Transgene Itself Toxic? Can it be Transferred to the
Genome of a Consumer?
Humans typically consume a minimum of 0.1 to 1 gram of
DNA in their diet each day (Doerfler, 2000). Therefore, the
transgene in a genetically engineered plant is not a new type of
material to our digestive systems, and it is present in extremely
small amounts. In transgenic corn, the transgenes represent
about 0.0001% of the total DNA (Lemaux and Frey, 2002).
Decades of research indicate that dietary DNA has no direct
toxicity itself. On the contrary, exogenous nucleotides have
been shown to play important beneficial roles in gut function
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and the immune system (Carver, 1999). Likewise, there is no
compelling evidence for the incorporation and expression of
plant-derived DNA, whether as a transgene or not, into the
genomes of consuming organisms. Defense processes have
evolved, including extensive hydrolytic breakdown of the
DNA during digestion, excision of integrated foreign DNA
from the host genome, and silencing of foreign gene expression
by targeted DNA methylation, that prevent the incorporation or
expression of foreign DNA (Doerfler, 1991, 2000). Although
much remains to be learned about the fate of dietary DNA in
mammalian systems (Doerfler, 2000), the possibility of adverse
effects arising from the presence of transgenic DNA in foods,
either by direct toxicity or gene transfer, is minimal (FAO/
WHO, 2000; Royal Society, 2002).
Does the Product Encoded by the Transgene Present a Risk
to Consumers or Handlers?
The potential toxicity of the transgene product must be
considered on a case-by-case basis. Particular attention must be
paid if the transgene produces a known toxin (such as the
Bacillus thuringiensis [Bt] endotoxins) or a protein with aller-
genic properties.
Production of toxins. The level of risk of these gene prod-
ucts to consumers and those involved in food production can be
and is evaluated by standard toxicological methods. The toxi-
cology testing for the Bt endotoxins typifies this approach and
has been described in detail by the U.S. EPA (1998, 2001). The
safety of most Bt toxins is assured by their easy digestibility as
well as by their lack of intrinsic activity in mammalian systems
(Betz et al., 2000; Kuiper et al., 2001; Siegel, 2001). In this
case, the good understanding of the mechanism of action of Bt
toxins, and the selective nature of their biochemical effects on
insect systems, increases the degree of certainty of the safety
evaluations. However, each new transgenic product must be
considered individually, based on exposure levels and its po-
tency in causing any toxic effects, as is typical of current risk
assessment paradigms for chemical agents.
Production of allergens. Allergenicity is one of the major
concerns about food derived from transgenic crops. However,
it is important to keep in mind that eating conventional food is
not risk-free; allergies occur with many known and even new
conventional foods. For example, the kiwi fruit was introduced
into the U.S. and the European markets in the 1960s with no
known human allergies; however, today there are people aller-
gic to this fruit (Pastorello et al., 1998). The issues that have to
be addressed regarding the potential allergenicity of BD foods
are:
● Do the products of novel genes have the ability to elicit
allergic reactions in individuals who are already sensitized to
the same, or a structurally similar, protein?
● Will transgenic techniques alter the level of expression of
existing protein allergens in the host crop plant?
● Do the products of novel genes engineered into food
plants have the ability to induce de novo sensitization among
susceptible individuals?
Considerable scientific resources are being committed to
determine the most appropriate and accurate approaches for
identifying and characterizing potentially allergenic proteins.
The first systematic approach to allergenicity assessment was
developed by the International Life Sciences Institute (ILSI) in
collaboration with the International Food Biotechnology Coun-
cil and was published in 1996 (Metcalfe et al., 1996). The
hierarchical approach described therein has been reviewed and
revised by the World Health Organization (WHO) and the
Food and Agriculture Organization of the United Nations
(FAO) (FAO/WHO, 2001b). The main approaches currently
used in the evaluation of allergenicity are:
● Determinations of structural similarity, sequence homol-
ogy, and serological identity. The objective is to determine
whether, and to what extent, the novel protein of interest
resembles other proteins that are known to cause allergy among
human populations. There are essentially three generic ap-
proaches. The first is to examine the overall structural similar-
ity between the protein of interest and known allergens. The
second is to determine, using appropriate databases, whether
the novel protein is similar to known allergens with respect to
either overall amino acid homology, or to discrete areas of the
molecule where complete sequence identity with a known
allergen may indicate the presence of shared epitopes. The
third approach is to determine whether specific IgE antibodies
in serum drawn from sensitized subjects are able to recognize
the protein of interest.
● Assessment of proteolytic stability. There exists a good,
but incomplete, correlation between the resistance of proteins
to proteolytic digestion and their allergenic potential, the the-
ory being that relative resistance to digestion will facilitate
induction of allergic responses, provided the protein possesses
allergenic properties (Astwood et al., 1996). One approach,
therefore, is to characterize the susceptibility of the protein of
interest to digestion by pepsin or in a simulated gastric fluid.
However, this approach alone may not be sufficient to identify
cross-reactive proteins with the potential to elicit allergic re-
sponses in food- or latex-sensitized individuals as in the case of
oral allergy syndrome or latex-fruit syndrome (Yagami et al.,
2000). Nor are considerations of stability to digestion neces-
sarily relevant for allergens that act through dermal or inhala-
tion exposure and that may have significance for worker health.
In these cases, other approaches such as structural homology
searches and the use of animal models may be effective in
identifying potential new allergens.
● Use of animal models. Currently there are no widely
accepted or thoroughly evaluated animal models available for
the identification of protein allergens. Nevertheless, progress is
being made and methods based on the characterization of
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allergic responses or allergic reactions in rodents and other
species have been described (Kimber and Dearman, 2001).
Although testing strategies for allergens are still evolving
and no single test is fully predictive of human responses, the
approaches outlined above, when used in combination, allow
scientists to address questions of potential allergenicity, and
these will increase in precision and certainty with time. Con-
siderations of this type led U.S. federal agencies to deny
approval of StarLink corn for human consumption because of
the possibility that its Bt protein, Cry9C, may be a human
allergen. This protein had been modified to slow its digestion
and prolong its effect in the insect gut and this change rendered
the protein less digestible in the human gut as well. After the
accidental introduction of StarLink corn into the human food
chain, a limited number of illnesses among consumers were
reported. These were investigated by the Centers for Disease
Control, who found no evidence that the corn products were
responsible (CDC, 2001). However, although this study is
reassuring, methodological limitations make it less than con-
clusive (Kuiper et al., 2001), and it cannot eliminate the
possibility that some adverse effects may have occurred that
were not reported. Because of this incident, StarLink corn is no
longer marketed. With the exception of Cry9C, none of the
engineered proteins in foods so far evaluated through the FDA
consultation process has had the characteristics of an allergen.
The only documented case where a human allergen was
introduced into a food component by genetic engineering oc-
curred when attempts were made to improve the nutritional
quality of soybeans using a brazil nut protein, the methionine-
rich 2S albumin. Allergies to the brazil nut have been docu-
mented (Arshad et al., 1991), and while still in precommercial
development, testing of these new soybeans for allergenicity
was conducted in university and industrial laboratories. It was
found that serum from people allergic to Brazil nuts also
reacted to the new soybean (Nordlee et al., 1996). Once this
was discovered, further development of the new soybean va-
riety was halted and it was never marketed. This work led to
the identification of the major protein associated with Brazil
nut allergy, which was previously unknown (Nordlee et al.,
1996).
Will Insertion of the Transgene Increase the Potential
Hazard from Toxins or Pharmacologically Active
Substances Present in the Host?
Concern has been expressed about the randomness with
which genes are inserted into the host by current genetic
engineering processes. This could, and does, result in pleiotro-
pic and insertional mutagenic effects. The former term refers to
the situation where a single gene causes multiple changes in the
host phenotype and the latter to the situation where the inser-
tion of the new gene induces changes in the expression of other
genes. Such changes due to random insertion might cause the
silencing of genes, changes in their level of expression, or,
potentially, the turning on of existing genes that were not
previously being expressed. Pleiotropic effects could be man-
ifested as unexpected new metabolic reactions arising from the
activity of the inserted gene product on existing substrates or as
changes in flow rates through normal metabolic pathways
(Conner and Jacobs, 1999).
Unexpected and potentially undesirable pleiotropic or mu-
tagenic changes in the genome of the host do occur (e.g., see a
recent listing by Kuiper et al., 2001), but these would likely be
revealed by their effects on the development, growth, or fer-
tility of the host, or by the extensive testing of its chemical
composition compared with isogenic untransformed plants,
which is a necessary part of any safety evaluation of transgenic
crops.
In the U.S., since 1987, the USDA Animal and Plant Health
Inspection Service has completed over 5000 field trials with
more than 70 different transgenic plant species. The only
unexpected result was a mutation in a color gene and gene
silencing through changes in the methylation status of these
genes that led to unexpected color patterns in petunia flowers.
Both of these effects are also seen in conventional plant breed-
ing (Meyer et al., 1992). While the possibility of an undetected
increase in a toxic component in a new food cannot be entirely
eliminated, the current safeguards make this unlikely, and no
toxicologically or nutritionally significant changes of this type
are evident in the transgenic plants so far marketed for food
production.
Substantial public concern about the safety of BD products
was raised in 1989 when a number of cases of eosinophilia-
myalgia syndrome (EMS) were reported among users of the
amino acid tryptophan as a dietary supplement. By mid-1993,
37 deaths had been attributed to this outbreak (Mayeno and
Gleich, 1994). The development of the syndrome appeared
among users of some batches of the supplement after a change
in the manufacturing process that included the use of a new
genetically modified microorganism in the fermentation. How-
ever, concomitant with this change were additional alterations
in certain filtration and purification steps used previously in the
manufacturing process. The exact cause of the outbreak and the
nature of the toxic impurity have not been established with
certainty. Thus, it is not possible to determine whether the
change in purification, the genetic engineering of the organism,
or some other factor or factors were to blame (Mayeno and
Gleich, 1994). A subsequent investigation revealed that cases
of EMS also occurred among consumers of tryptophan before
the GM organism was introduced into the manufacturing pro-
cess, although at a lower incidence. Thus, the genetic modifi-
cations might have caused an increase in the level of the agent
that was responsible for tryptophan-associated EMS, but it did
not create a novel toxicant (Sullivan et al., 1996). This event is
troubling in that the tryptophan would be regarded as highly
purified (99.6% or higher), and no adequate animal model has
been found to replicate EMS, a probable autoimmune disease.
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This illustrates that toxicology has limits in its ability to
explain and predict adverse effects in humans.
These examples indicate that careful analysis of the changes
in BD organisms is necessary to ensure against unexpected
alterations in the levels of toxins, allergens, and essential
nutrients. This analysis will be particularly critical if, as seems
likely, engineering of the synthetic pathways of secondary
metabolites is undertaken in plants, e.g., to increase their
resistance to insects and pathogens or to produce compounds of
pharmaceutical value. Such changes might create new and
unanticipated secondary compounds with unknown toxic prop-
erties. New approaches to profiling changes in metabolites,
proteins, and gene expression (Kuiper et al., 2001) may be
helpful in such cases.
Does the Possible Transfer of Antibiotic Resistance Marker
Genes from the Ingested BD Food to Gut Microbes
Present a Significant Human Hazard?
The development of antibiotic resistance among pathogenic
bacteria is a significant human health issue. However, no
contribution to antibiotic resistance in gut bacteria arising from
antibiotic resistance markers in BD foods has been docu-
mented. For several reasons, including the efficient destruction
of the resistance gene in the human gut and the very low
intrinsic rate of plant–microbe gene transfer, any contribution
from this source is expected to be extremely small (Royal
Society, 1998). Genes for resistance to kanamycin and related
antibiotics already occur quite commonly in the environment,
including in the flora of the human gut, which naturally con-
tains about 1 trillion (1012) kanamycin- or neomycin-resistant
bacteria (Flavell et al., 1992). Even if the occasional transfer of
resistance from plant to bacterium did occur, the practical
impact would be negligible. However, since any increase in
antibiotic resistance is recognized as undesirable and the tech-
nology is now available to omit the use of such marker genes,
future genetically modified organisms are unlikely to contain
them (e.g., see Goldsbrough et al., 1996; Koprek et al., 2000).
Thus, concerns related to their use are likely to diminish.
Will Genetic Transformation Adversely Affect the Nutritional
Value of the Host?
In the USA, the FDA is entrusted with assuring that the
nutritional composition of BD foods is substantially equivalent
to that of the nonmodified food. Studies are performed to
determine whether nutrients, vitamins, and minerals in the new
food occur at the same level as in the conventionally bred food
sources (e.g., see Berberich et al.,1996; Sidhu et al., 2000). A
typical example is the case of Roundup Ready soybeans. In this
case, the protein, oil, fiber, ash, carbohydrates, and moisture
content and the amino acid and fatty acid composition in seeds
and toasted soybean meal were compared with conventional
soybeans. Fatty acid compositions and protein or amino acid
levels of soybean oil were compared and special attention was
given to checking the levels of antinutrients typically found in
soybeans, e.g., trypsin inhibitors, lectins, and isoflavones
(Padgette et al., 1996).
One difference between the conventional and nonconven-
tional soybeans was detected in defatted, nontoasted soybean
meal, the starting material for commercially utilized soybean
protein, which is not itself consumed. In this material, trypsin
inhibitor levels were 11–26% higher in the transgenic soy-
beans. The levels of the trypsin inhibitors were similar in all
lines in the seeds and in defatted, toasted soybean meal, the
form used in foods. Except for this difference in trypsin inhib-
itor levels, all other nutritional aspects were equivalent be-
tween the transgenic line and the conventional soybean culti-
vars. Feeding studies demonstrated that there were no evident
differences in nutritional value between the conventional and
transgenic soybeans in rats, chickens, catfish, and dairy cattle
(Hammond et al., 1996). Domestic animal feeding studies with
a number of other transgenic crops (e.g., see Kuiper et al.,
2001) have similarly shown no significant adverse changes in
nutritional value.
Will the Transgene Product Adversely Affect Nontarget
Organisms?
In addition to the general concerns addressed that relate to food
safety, additional attention is needed when the gene product is
pesticidal or otherwise may be toxic to nontarget organisms that
consume it. The effects of each transgene product that is designed
for pesticidal effects must be evaluated on a case-by-case basis
against target and nontarget organisms under specific field growth
conditions for each transgenic crop. The foremost current example
of this is the incorporation of Bt genes into crop plants for insect
control. The toxic properties of Bt endotoxins to both target and
nontarget species of many kinds are well known (Betz et al.,
2000). They show a narrow range of toxicity limited to specific
groups of insects, primarily Lepidoptera, Coleoptera, or Diptera,
depending on the Bt strain. Nevertheless, Bt-producing plants
have been tested broadly to determine whether any alteration in
this limited spectrum of toxicity has occurred, without the discov-
ery of any unexpected results (see Gatehouse et al., 2002; Lozzia
et al., 1998; Orr and Landis, 1997; and Pilcher et al., 1997 for
examples of such studies). Exotoxins and enterotoxins, which are
much more broadly toxic than the endotoxins, are also produced
by some Bt strains, but these are not present in the transformed
plant, because their genes are not transferred into the crop.
In plants transformed with Bt genes to control lepidopterans,
toxicity to nontarget lepidopterans would be expected if expo-
sure occurs by feeding on the transformed crop. Particular
concern has been expressed over the potential toxicity of the Bt
toxin in corn pollen to the Monarch butterfly after initial
laboratory studies showed increased mortality in larvae fed on
leaves dusted with transgenic pollen (Losey et al., 1999).
However, most transgenic corn pollen contains much lower
nonlethal levels of Bt toxins than the strain used in this study,
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and there is only a limited synchrony between the feeding
period of the most sensitive younger larvae and the period
when corn pollen is shed. Also, corn pollen does not typically
move far beyond the borders of the field, leaving significant
amounts of milkweed uncontaminated in many locations. For
these reasons, a detailed risk assessment concluded it is un-
likely that a substantial risk to these butterflies exists in the
field since only a negligible portion of the population is ex-
posed to toxic levels of Bt (Gatehouse et al., 2002; Sears et al.,
2001). Beyond the question of the potential toxicity of Bt corn
to such valued insects, it is also important to recollect that the
common alternative is to spray corn with synthetic insecticides,
which are not as selective as the Bt toxin. In a sweet corn field
containing milkweed plants and treated with a synthetic pyre-
throid for insect control, 91–100% of the monarch butterfly
larvae placed on the milkweed leaves after spraying were
killed. In plots where Bt sweet corn was planted and the pollen
fell naturally on the milkweed leaves, larval death rates were
much lower (7–20%) and indistinguishable from those in un-
treated non-Bt corn plots (Stanley-Horn et al., 2001).
Future Challenges in the Assessment of the
Safety of BD Foods
Current safety assessment methodologies are focused primarily
on the evaluation of the toxicity of single chemicals. Food is a
complex mixture of many chemicals. Using animal models, the
evaluation of most aspects of the safety of single components of
the diet, such as a Bt toxin, is possible using widely accepted
protocols. Future projects may involve more complicated manip-
ulations of plant chemistry. In this case, safety testing will be more
challenging. Whole foods cannot be tested with the high dose
strategy currently used for single chemicals to increase the sensi-
tivity in detecting toxic endpoints (MacKenzie, 1999; Royal So-
ciety of Canada, 2001). Also, the question of potential deleterious
interactions between new or enhanced levels of known toxic
agents in BD foods will undoubtedly be raised. The safety testing
of multiple combinations of chemicals remains a difficult propo-
sition for toxicologists. In view of these challenges, there is a clear
need for the development of effective protocols to allow the
assessment of the safety of whole foods (NRC, 2000; Royal
Society of Canada, 2001).
CONCLUSIONS
The responsibility of toxicologists is to assess whether foods
derived through biotechnology are at least as safe as their
conventional counterparts and to ascertain that any levels of
additional risk are clearly defined. In achieving this goal, it is
important to recognize that it is the food product itself, rather
than the process through which it is made, that should be the
focus of attention. In assessing safety, the use of the substantial
equivalency concept provides guidance as to the nature of any
new hazards.
Scientific analysis indicates that the process of BD food
production is unlikely to lead to hazards of a different nature
from those already familiar to toxicologists. The safety of
current BD foods, compared with their conventional counter-
parts, can be assessed with reasonable certainty using estab-
lished and accepted methods of analytical, nutritional, and
toxicological research.
A significant limitation may occur in the future if transgenic
technology results in more substantial and complex changes in
a foodstuff. Methods have not yet been developed by which
whole foods (as compared with single chemical components)
can be fully evaluated for safety. Progress also needs to be
made in developing definitive methods for the identification
and characterization of protein allergens, and this is currently a
major focus of research. Improved methods of profiling plant
and microbial metabolites, proteins, and gene expression may
be helpful in detecting unexpected changes in BD organisms
and in establishing substantial equivalence.
The level of safety of current BD foods to consumers appears
to be equivalent to that of traditional foods. Verified records of
adverse health effects are absent, although the current passive
reporting system would probably not detect minor or rare adverse
effects, nor can it detect a moderate increase in common effects
such as diarrhea. However, this is no guarantee that all future
genetic modifications will have such apparently benign and pre-
dictable results. A continuing evolution of toxicological method-
ologies and regulatory strategies will be necessary to ensure that
this level of safety is maintained.
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